UK markets closed

Haleon plc (HLN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
277.45+11.45 (+4.30%)
At close: 05:10PM BST
Full screen
Previous close266.00
Bid277.75 x N/A
Ask277.85 x N/A
Day's range269.25 - 278.95
52-week range241.17 - 337.40
Avg. volume31,792,429
Market cap25.621B
Beta (5Y monthly)N/A
PE ratio (TTM)17.34
EPS (TTM)0.16
Earnings date20 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est328.33
  • The Guardian

    The only party not getting heartburn over GSK demerger is the lawyers

    The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

  • PA Media: Money

    Haleon reports strong revenue growth in first results since GSK split

    The company, which owns health products Sensodyne and Panadol, posted a 13.4% rise in its revenue to £5.2 billion in the first half of the year.

  • Reuters

    Haleon believes it is not liable for any potential Zantac liabilities

    LONDON (Reuters) -Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday. Zantac, originally marketed by a forerunner of GSK , has been sold by several companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi as well as a plethora of generic drugmakers. Haleon, spun out of GSK as an independent company in July as the world's biggest standalone consumer health business, comprises consumer health assets once owned by GSK and Pfizer.